Regulators of endothelial and epithelial barrier integrity and function in acute lung injury

Rudolf Lucas, Alexander Dmitriyevich Verin, Stephen Matthew Black, John D. Catravas

Research output: Contribution to journalComment/debate

157 Citations (Scopus)

Abstract

Permeability edema is a life-threatening complication accompanying acute lung injury (ALI), severe pneumonia and the acute respiratory distress syndrome (ARDS), which can be associated with a reduced alveolar liquid clearance (ALC) capacity, a disruption of the alveolar epithelial barrier, and an increased capillary endothelial permeability. Bacterial and viral infections can directly promote pulmonary endothelial hyperpermeability and indirectly decrease the function and/or expression of ion transporters regulating ALC in type II alveolar epithelial cells, by means of inducing a strong inflammatory and oxidative stress response in the infected lungs. Apart from ventilation strategies, no standard treatment exists for permeability edema, making the search for novel regulators of endothelial and epithelial hyperpermeability and dysfunction important. Here, we present an overview of recently identified substances that inhibit and/or reverse endothelial barrier disruption and permeability or alveolar epithelial dysfunction: (1) zinc chelators, which were shown to attenuate the effects of oxidative stress on the pulmonary endothelium; (2) peroxisome proliferator activated receptor (PPAR) ligands, which have been shown to exert anti-inflammatory effects, by decreasing the expression of pro-inflammatory genes; (3) extracellular ATP, produced during inflammation, which induces a rapid and dose-dependent increase in transendothelial electrical resistance (TER) across pulmonary endothelial cells; (4) the lectin-like domain of TNF, which is spatially distinct from the receptor binding sites and which protects from hydrostatic and permeability edema and (5) Hsp90 inhibitors, which prevent and repair toxin-induced hyperpermeability. Unraveling the mechanism of action of these agents could contribute to the development of novel therapeutic strategies to combat permeability edema.

Original languageEnglish (US)
Pages (from-to)1763-1772
Number of pages10
JournalBiochemical Pharmacology
Volume77
Issue number12
DOIs
StatePublished - Jun 15 2009

Fingerprint

Oxidative stress
Acute Lung Injury
Permeability
Edema
Peroxisome Proliferator-Activated Receptors
Acoustic impedance
Endothelial cells
Liquids
Chelating Agents
Lung
Lectins
Ventilation
Zinc
Repair
Anti-Inflammatory Agents
Genes
Adenosine Triphosphate
Binding Sites
Ions
Ligands

Keywords

  • ATP
  • Lectin-like domain of TNF
  • PPAR agonists
  • Permeability edema
  • hsp90 inhibitors

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

Regulators of endothelial and epithelial barrier integrity and function in acute lung injury. / Lucas, Rudolf; Verin, Alexander Dmitriyevich; Black, Stephen Matthew; Catravas, John D.

In: Biochemical Pharmacology, Vol. 77, No. 12, 15.06.2009, p. 1763-1772.

Research output: Contribution to journalComment/debate

@article{439909fe38bc4bfdb974cfd90ae98f80,
title = "Regulators of endothelial and epithelial barrier integrity and function in acute lung injury",
abstract = "Permeability edema is a life-threatening complication accompanying acute lung injury (ALI), severe pneumonia and the acute respiratory distress syndrome (ARDS), which can be associated with a reduced alveolar liquid clearance (ALC) capacity, a disruption of the alveolar epithelial barrier, and an increased capillary endothelial permeability. Bacterial and viral infections can directly promote pulmonary endothelial hyperpermeability and indirectly decrease the function and/or expression of ion transporters regulating ALC in type II alveolar epithelial cells, by means of inducing a strong inflammatory and oxidative stress response in the infected lungs. Apart from ventilation strategies, no standard treatment exists for permeability edema, making the search for novel regulators of endothelial and epithelial hyperpermeability and dysfunction important. Here, we present an overview of recently identified substances that inhibit and/or reverse endothelial barrier disruption and permeability or alveolar epithelial dysfunction: (1) zinc chelators, which were shown to attenuate the effects of oxidative stress on the pulmonary endothelium; (2) peroxisome proliferator activated receptor (PPAR) ligands, which have been shown to exert anti-inflammatory effects, by decreasing the expression of pro-inflammatory genes; (3) extracellular ATP, produced during inflammation, which induces a rapid and dose-dependent increase in transendothelial electrical resistance (TER) across pulmonary endothelial cells; (4) the lectin-like domain of TNF, which is spatially distinct from the receptor binding sites and which protects from hydrostatic and permeability edema and (5) Hsp90 inhibitors, which prevent and repair toxin-induced hyperpermeability. Unraveling the mechanism of action of these agents could contribute to the development of novel therapeutic strategies to combat permeability edema.",
keywords = "ATP, Lectin-like domain of TNF, PPAR agonists, Permeability edema, hsp90 inhibitors",
author = "Rudolf Lucas and Verin, {Alexander Dmitriyevich} and Black, {Stephen Matthew} and Catravas, {John D.}",
year = "2009",
month = "6",
day = "15",
doi = "10.1016/j.bcp.2009.01.014",
language = "English (US)",
volume = "77",
pages = "1763--1772",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Regulators of endothelial and epithelial barrier integrity and function in acute lung injury

AU - Lucas, Rudolf

AU - Verin, Alexander Dmitriyevich

AU - Black, Stephen Matthew

AU - Catravas, John D.

PY - 2009/6/15

Y1 - 2009/6/15

N2 - Permeability edema is a life-threatening complication accompanying acute lung injury (ALI), severe pneumonia and the acute respiratory distress syndrome (ARDS), which can be associated with a reduced alveolar liquid clearance (ALC) capacity, a disruption of the alveolar epithelial barrier, and an increased capillary endothelial permeability. Bacterial and viral infections can directly promote pulmonary endothelial hyperpermeability and indirectly decrease the function and/or expression of ion transporters regulating ALC in type II alveolar epithelial cells, by means of inducing a strong inflammatory and oxidative stress response in the infected lungs. Apart from ventilation strategies, no standard treatment exists for permeability edema, making the search for novel regulators of endothelial and epithelial hyperpermeability and dysfunction important. Here, we present an overview of recently identified substances that inhibit and/or reverse endothelial barrier disruption and permeability or alveolar epithelial dysfunction: (1) zinc chelators, which were shown to attenuate the effects of oxidative stress on the pulmonary endothelium; (2) peroxisome proliferator activated receptor (PPAR) ligands, which have been shown to exert anti-inflammatory effects, by decreasing the expression of pro-inflammatory genes; (3) extracellular ATP, produced during inflammation, which induces a rapid and dose-dependent increase in transendothelial electrical resistance (TER) across pulmonary endothelial cells; (4) the lectin-like domain of TNF, which is spatially distinct from the receptor binding sites and which protects from hydrostatic and permeability edema and (5) Hsp90 inhibitors, which prevent and repair toxin-induced hyperpermeability. Unraveling the mechanism of action of these agents could contribute to the development of novel therapeutic strategies to combat permeability edema.

AB - Permeability edema is a life-threatening complication accompanying acute lung injury (ALI), severe pneumonia and the acute respiratory distress syndrome (ARDS), which can be associated with a reduced alveolar liquid clearance (ALC) capacity, a disruption of the alveolar epithelial barrier, and an increased capillary endothelial permeability. Bacterial and viral infections can directly promote pulmonary endothelial hyperpermeability and indirectly decrease the function and/or expression of ion transporters regulating ALC in type II alveolar epithelial cells, by means of inducing a strong inflammatory and oxidative stress response in the infected lungs. Apart from ventilation strategies, no standard treatment exists for permeability edema, making the search for novel regulators of endothelial and epithelial hyperpermeability and dysfunction important. Here, we present an overview of recently identified substances that inhibit and/or reverse endothelial barrier disruption and permeability or alveolar epithelial dysfunction: (1) zinc chelators, which were shown to attenuate the effects of oxidative stress on the pulmonary endothelium; (2) peroxisome proliferator activated receptor (PPAR) ligands, which have been shown to exert anti-inflammatory effects, by decreasing the expression of pro-inflammatory genes; (3) extracellular ATP, produced during inflammation, which induces a rapid and dose-dependent increase in transendothelial electrical resistance (TER) across pulmonary endothelial cells; (4) the lectin-like domain of TNF, which is spatially distinct from the receptor binding sites and which protects from hydrostatic and permeability edema and (5) Hsp90 inhibitors, which prevent and repair toxin-induced hyperpermeability. Unraveling the mechanism of action of these agents could contribute to the development of novel therapeutic strategies to combat permeability edema.

KW - ATP

KW - Lectin-like domain of TNF

KW - PPAR agonists

KW - Permeability edema

KW - hsp90 inhibitors

UR - http://www.scopus.com/inward/record.url?scp=67349132318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349132318&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2009.01.014

DO - 10.1016/j.bcp.2009.01.014

M3 - Comment/debate

C2 - 19428331

AN - SCOPUS:67349132318

VL - 77

SP - 1763

EP - 1772

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 12

ER -